Singapore's first locally made antibody-drug conjugate approved for clinical trials

An antibody-drug conjugate called EBC-129 will be the first made-in-Singapore antibody-drug conjugate to be approved to enter clinical trials by the US Food and Drug Administration. This drug is able to selectively target cancer cells across a range of solid tumours -- killing it, while sparing normal, healthy cells. Dr Andre Choo, deputy executive director at A*STAR's Bioprocessing Technology Institute, and Dr Veronica Diermayr, asset development leader at the Experimental Drug Development Centre, shared more about the development process.

Subscribe to our channel here: https://cna.asia/youtubesub

Subscribe to our news service on Telegram: https://cna.asia/telegram

Follow us:
CNA: https://cna.asia
CNA Lifestyle: http://www.cnalifestyle.com
Facebook:   / channelnewsasia  
Instagram:   / channelnewsasia  
Twitter:   / channelnewsasia  
TikTok:   / channelnewsasia